GOLDFISCHER CARL, Director, subtracted 11,675 shares of CymaBay Therapeutics, Inc. (CBAY) from its portfolio at the rate of $9.02 per share valuing $105,328 on Feb 07. The insider left behind 0 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of CymaBay Therapeutics, Inc. (CBAY) was $6.75. Currently, the 1st Resistance Point for this stock is $7.07, with a 2nd Resistance Point sitting at $7.39. Meanwhile, this company’s stock has a 1st Support Level at $6.22 and a 2nd Support Level at $5.70. CymaBay Therapeutics, Inc. (CBAY) stock has lost -$4.65, or -40.79%, in the past five days. In the last full month, these shares have lost -$5.61, or -45.39%. In the past three months, this stock’s price has fallen by -$6.54, or -49.21%. This year-to-date, CymaBay Therapeutics, Inc. (CBAY) shares have lost -$1.12, or -14.23%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For CymaBay Therapeutics, Inc. (CBAY) stock, 100% of short-term indicators suggest that these shares are a “ Sell .” Meanwhile, 100% of medium-term indicators point to this stock being a “ Sell .” Looking further ahead, 33% of long-term indicators suggest that this stock is a “ Sell .”
With 68,694 K shares outstanding, this company currently has a market capitalization of $423,842K. CymaBay Therapeutics, Inc. (CBAY) generates annual net income of -$72,550 K. This stock has generated a 1-Year Total Return of -48.63%, a 3-Year Total Return of 275.00%, and a 5-year Total Return of 5.63%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in Mar-19, CymaBay Therapeutics, Inc. (CBAY) reported earnings of -$0.37 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.34 per share, representing a -0.03 difference and -9.53% surprise. In the previous quarter ending in Dec-18, the reported earnings of -$0.32 represented a 0.04 difference from the consensus estimate calling for -$0.36 per share, which was a -10.56% surprise.
For the current fiscal quarter, which is set to end in 06/2019, the average earnings estimate is -$0.36 per share. This estimate came from a total of 8 Wall Street Analysts. Of those market experts, the high estimate was -$0.34 and the low estimate was -$0.41. In the year-ago quarter, CymaBay Therapeutics, Inc. (CBAY) generated per-share earnings of -$0.30. If the analysts are correct about the current quarter’s earnings, the growth will be -20.00% .
Turning our focus now to insider trading activity, there have been 0 purchases (0 shares in total) and 0 sale (0 shares in total) in the last 3 months. In the last 6 months, there have been 3 insider buys amounting to 21,675 shares and 3 insider sales amounting to 154,056 shares. In the past full year, 6 insider purchases were made (involving 36,675 shares) and 4 insider sell-offs equivalent to 159,056 shares.
Moving onto liquidity, CymaBay Therapeutics, Inc. (CBAY) has a Current Ratio of 12.60, a Quick Ratio of 12.60 and a Cash Ratio of 12.39.